![浑水做空奇努克治疗公司_第1页](http://file4.renrendoc.com/view/c7f62299e22cd7325f120854a00f24b4/c7f62299e22cd7325f120854a00f24b41.gif)
![浑水做空奇努克治疗公司_第2页](http://file4.renrendoc.com/view/c7f62299e22cd7325f120854a00f24b4/c7f62299e22cd7325f120854a00f24b42.gif)
![浑水做空奇努克治疗公司_第3页](http://file4.renrendoc.com/view/c7f62299e22cd7325f120854a00f24b4/c7f62299e22cd7325f120854a00f24b43.gif)
![浑水做空奇努克治疗公司_第4页](http://file4.renrendoc.com/view/c7f62299e22cd7325f120854a00f24b4/c7f62299e22cd7325f120854a00f24b44.gif)
![浑水做空奇努克治疗公司_第5页](http://file4.renrendoc.com/view/c7f62299e22cd7325f120854a00f24b4/c7f62299e22cd7325f120854a00f24b45.gif)
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
MuddyWatersCapitalLLC
info@DirectorofResearch:CarsonC.Block
TheseTermsofUsegoverncurrentreportspublishedbyMuddyWatersResearchandsupersedeanypriorTermsofUseforolderreportsofMuddyWatersResearch,whichyoumaydownloadfromtheMuddyWatersResearch’swebsite.
ThereportsonthiswebsitehavebeenpreparedbyMuddyWatersCapitalLLC(“MuddyWatersCapital”).WerefertoMuddyWatersResearchandMuddyWatersCapitalcollectivelyas“MuddyWaters”andindividuallytheseentitiesarereferredtoasa“MuddyWatersEntity”.Youshouldassumethat,asofthepublicationdateofaMuddyWatersreport,MuddyWatersRelatedPersons(possiblyalongwithorthroughitsmembers,partners,affiliates,employees,and/orconsultants),MuddyWatersRelatedPersonsclientsand/orinvestorsand/ortheirclientsand/orinvestorshaveashortpositioninoneormoreofthesecuritiesofaCoveredIssuer(and/oroptions,swaps,andotherderivativesrelatedtooneormoreofthesesecurities),andthereforestandtorealizesignificantgainsintheeventthatthepricesofeitherequityordebtsecuritiesofaCoveredIssuerdeclineorappreciate.MuddyWatersResearch,MuddyWatersCapitaland/ortheMuddyWatersRelatedPersonsintendtocontinuetransactinginthesecuritiesofCoveredIssuersforanindefiniteperiodafteraninitialreportonaCoveredPerson,andsuchpersonmaybelong,short,orneutralatanytimehereafterregardlessoftheirinitialpositionandviewsasstatedintheresearchreportpublishedbyMuddyWatersResearchorMuddyWatersCapital.NeitherMuddyWatersResearchnorMuddyWatersCapitalwillupdateanyreportorinformationonitswebsitetoreflectchangesinpositionsthatmaybeheldbyaMuddyWatersRelatedPerson.Eachreportspecifiesthepublisherandownerofthatreport.Allreportsareforinformationalpurposesonly.Undernocircumstancesshouldanyofthesereportsoranyinformationhereinbeconstruedasinvestmentadvice,orasanoffertosellorthesolicitationofanoffertobuyanysecuritiesorotherfinancialinstruments.
MuddyWatersResearchisanonlineresearchpublicationthatproducesduediligence-basedreportsonpubliclytradedsecurities,andMuddyWatersCapitalLLCisaninvestmentadviserregisteredwiththeU.S.SecuritiesandExchangeCommission.ThereportsarethepropertyoftheapplicableMuddyWatersEntitythatpublishedthatreport.ThiswebsiteisownedbyMuddyWatersResearch.Theopinions,informationandreportssetforthhereinaresolelyattributabletotheapplicableMuddyWatersEntityandarenotattributabletoanyMuddyWatersRelatedPerson(definedbelow)(otherthantheapplicableMuddyWatersEntity).
Bydownloadingfrom,orviewingmaterialonthiswebsite,youagreetothefollowingTermsofUse.Youagreethatuseoftheresearchonthiswebsiteisatyourownrisk.You(oranypersonyouareactingasagentfor)agreetoholdharmlessMuddyWatersResearch,MuddyWatersCapitalanditsaffiliatesandrelatedparties,including,butnotlimitedtoanyprincipals,officers,directors,employees,members,clients,investors,consultantsandagents(collectively,the“MuddyWatersRelatedPersons”)foranydirectorindirectlosses(includingtradinglosses)attributabletoanyinformationonthiswebsiteorinaresearchreport.Youfurtheragreetodoyourownresearchandduediligencebeforemakinganyinvestmentdecisionwithrespecttosecuritiesoftheissuerscoveredherein(each,a“CoveredIssuer”)oranyotherfinancialinstrumentsthatreferencetheCoveredIssueroranysecuritiesissuedbytheCoveredIssuer.Yourepresentthatyouhavesufficientinvestmentsophisticationtocriticallyassesstheinformation,analysisandopiniononthiswebsite.YoufurtheragreethatyouwillnotcommunicatethecontentsofreportsandothermaterialsonthissitetoanyotherpersonunlessthatpersonhasagreedtobeboundbytheseTermsofUse.Ifyouaccessthiswebsite,downloadorreceivethecontentsofreportsorothermaterialsonthiswebsiteonyourownbehalf,youagreetoandshallbeboundbytheseTermsofUse.Ifyouaccessthiswebsite,downloadorreceivethecontentsofreportsorothermaterialsonthiswebsiteasanagentforanyotherperson,youarebindingyourprincipaltothesesameTermsofUse.
Thisisnotanoffertosellorasolicitationofanoffertobuyanysecurity.NeitherMuddyWatersResearchnoranyMuddyWatersRelatedPerson(includingMuddyWatersCapital)areoffering,sellingorbuyinganysecuritytoorfromanypersonthroughthiswebsiteorreportsonthiswebsite.MuddyWatersResearchisaffiliatedwithMuddyWatersCapital.MuddyWatersCapitalisaninvestmentadviserwiththeU.S.SecuritiesandExchangeCommissionandisnotregisteredasinvestmentadviserinanyotherjurisdiction.MuddyWatersCapitaldoesnotrenderinvestmentadvicetoanyoneunlessithasaninvestmentadviser-clientrelationshipwiththatpersonevidencedinwriting.YouunderstandandagreethatMuddyWatersCapitaldoesnothaveanyinvestmentadvisoryrelationshipwithyouordoesnotowefiduciarydutiestoyou.Givinginvestmentadvicerequiresknowledgeofyourfinancialsituation,investmentobjectives,andrisktolerance,andMuddyWatersCapitalhasnosuchknowledgeaboutyou.
IfyouareintheUnitedKingdom,youconfirmthatyouareaccessingresearchandmaterialsasoronbehalfof:(a)aninvestmentprofessionalfallingwithinArticle19oftheFinancialServicesandMarketsAct2000(FinancialPromotion)Order2005(the“FPO”);or(b)highnetworthentityfallingwithinArticle49oftheFPO(eacha“PermittedRecipient”).InrelationtotheUnitedKingdom,theresearchandmaterialsonthiswebsitearebeingissuedonlyto,andaredirectedonlyat,personswhoarePermittedRecipientsand,withoutprejudicetoanyotherrestrictionsorwarningssetoutintheseTermsofUse,personswhoarenotPermittedRecipientsmustnotactorrelyontheinformationcontainedinanyoftheresearchormaterialsonthiswebsite.
TheresearchandreportspresentedonthiswebsiteexpresstheopinionoftheapplicableMuddyWatersEntityonly.Reportsarebasedongenerallyavailableinformation,fieldresearch,inferencesanddeductionsthroughtheapplicableMuddyWatersEntity’sduediligenceandanalyticalprocess.TothebestoftheapplicableMuddyWatersEntity’sabilityandbelief,allinformationcontainedhereinisaccurateandreliable,andhasbeenobtainedfrompublicsourcesthattheapplicableMuddyWatersEntitybelievetobeaccurateandreliable,andwhoarenotinsidersorconnectedpersonsoftheCoveredIssuersorwhomayotherwiseoweafiduciaryduty,dutyofconfidentialityoranyotherdutytotheCoveredIssuer(directlyorindirectly).However,suchinformationispresented“asis,”withoutwarrantyofanykind,whetherexpressorimplied.Withrespecttotheirrespectiveresearchreports,MuddyWatersResearchandMuddyWatersCapitalmakesnorepresentation,expressorimplied,astotheaccuracy,timeliness,orcompletenessofanysuchinformationorwithregardtotheresultstobeobtainedfromitsuse.Further,anyreportonthissitecontainsaverylargemeasureofanalysisandopinion.Allexpressionsofopinionaresubjecttochangewithoutnotice,andneitherMuddyWatersResearchnorMuddyWatersCapitalundertakestoupdateorsupplementanyreportsoranyoftheinformation,analysisandopinioncontainedinthem.
InnoeventshallMuddyWatersResearch,MuddyWatersCapitaloranyMuddyWatersRelatedPersonsbeliableforanyclaims,losses,costsordamagesofanykind,includingdirect,indirect,punitive,exemplary,incidental,specialor,consequentialdamages,arisingoutoforinanywayconnectedwithanyinformationonthiswebsite.ThislimitationofliabilityappliesregardlessofanynegligenceorgrossnegligenceofMuddyWatersResearch,MuddyWatersCapitaloranyMuddyWatersRelatedPersons.Youacceptallrisksinrelyingontheinformationonthiswebsite.
Youagreethattheinformationonthiswebsiteiscopyrighted,andyouthereforeagreenottodistributethisinformation(whetherthedownloadedfile,copies/images/reproductions,orthelinktothesefiles)inanymannerotherthanbyprovidingthefollowinglink:/research/.IfyouhaveobtainedresearchpublishedbyMuddyWatersResearchorMuddyWatersCapitalinanymannerotherthanbydownloadfromthatlink,youmaynotreadsuchresearchwithoutgoingtothatlinkandagreeingtotheTermsofUse.YoufurtheragreethatanydisputebetweenyouandMuddyWatersResearchanditsaffiliatesarisingfromorrelatedtothisreportand/ortheMuddyWatersResearchwebsiteorviewingthematerialhereonshallbegovernedbythelawsoftheStateofCalifornia,withoutregardtoanyconflictoflawprovisions.YouknowinglyandindependentlyagreetosubmittothepersonalandexclusivejurisdictionofthestateandfederalcourtslocatedinSanFrancisco,Californiaandwaiveyourrighttoanyotherjurisdictionorapplicablelaw,giventhatMuddyWatersResearchanditsaffiliatesarebasedinSanFrancisco,California.ThefailureofMuddyWatersResearchorMuddyWatersCapitaltoexerciseorenforceanyrightorprovisionoftheseTermsofUseshallnotconstituteawaiverofthisrightorprovision.YouagreethateachMuddyWatersRelatedPersonisathird-partybeneficiarytotheseTermsofUse.IfanyprovisionoftheseTermsofUseisfoundbyacourtofcompetentjurisdictiontobeinvalid,thepartiesneverthelessagreethatthecourtshouldendeavortogiveeffecttotheparties’intentionsasreflectedintheprovisionandrulethattheotherprovisionsoftheseTermsofUseremaininfullforceandeffect,inparticularastothisgoverninglawandjurisdictionprovision.Youagreethatregardlessofanystatuteorlawtothecontrary,anyclaimorcauseofactionarisingoutoforrelatedtothiswebsiteorthematerialonthiswebsitemustbefiledwithinone(1)yearaftertheoccurrenceoftheallegedharmthatgaverisetosuchclaimorcauseofaction,orsuchclaimorcauseofactionbeforeverbarred.
1/35
ChinookTherapeuticsInc:TooLittle,TooLate
MuddyWatersisshortChinookTherapeuticsInc(NASDAQ:KDNY)becausewebelieveitishighlyunlikelythatatrasentan,itsleadproductcandidate,willbeapprovedbytheFDA.Weconcludethatatrasentanisinefficaciousforchronickidneydisease.1Wealsoconcludethatatrasentanhasbeenshowntobeharmfultopatients’cardiovascularhealth.2AbbVie3andChinookseemtohavesystemicallymanipulatedresearchfindingsandpresentationonatrasentantoobscurethesetrialresults.Evenifatrasentanwereefficaciousandsafe,itwouldbeunlikelytogainapprovalbecauseacompetingdrug,sparsentan,hasreceivedacceleratedandexclusiveorphandrugapprovalbytheUSFDAforIgAnephropathy,theconditiontargetedinChinook’sonlyPhase3trial,theALIGNstudy.4
Fromtrialdata,atrasentanappearsinefficaciousforchronickidneydisease.Inthelargestavailablestudy,atrasentanhadnostatistically-significanteffectonadvancementtoend-stagerenaldisease,showingonlyaminornumericaldifferencebetweendrugandplacebogroups.5AlldifferencesinUACRandsystolicbloodpressurebetweenatrasentanandplacebopatientsdisappearedaftertrialcessation,whichsuggeststherewasnoactualimprovementintherateofrenaldecline.6,7,8ScientificliteraturerespondingtoSONARalsonotesthatthedrug’sreportedeffectsonUACRmaybeimplausiblyhigh.9HadtheRADARandSONARtrialperiodsfullyreportedhematocrit,webelievetheywouldhaveshownthatatrasentan’sprimaryeffectwasblooddilution–i.e.,ahemodynamiceffect.10,11Thisprobablehemodynamiceffectwasnotonlylikelyresponsibleforthetemporarilyimprovedbiomarkersobservedduringthetrial,butalsowouldposeserioushealthrisks.
Atrasentanisalsoharmfultopatients’health,especiallyolderandmorefragilepatientssuchasthosewithdiabetickidneydisease,thelargestpotentialpatientpopulation.12Thenumericaldifferenceinheartfailurebetweenatrasentanandplacebowasgreaterthanthenumericaldifferenceinpatients’progressiontoend-stagerenaldisease.13Acutekidneyinjurywashigher
1https://repo.dma.dp.ua/6035/1/SONAR.pdf
2https://repo.dma.dp.ua/6035/1/SONAR.pdf,
/ct2/show/results/NCT01858532?term=atrasentan&draw=2&rank=4
3FromwhichChinookin-licensedatrasentanin2019:2021KDNY10-K,pg.5.
4/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=6144175https://repo.dma.dp.ua/6035/1/SONAR.pdf,Table2.
6https://repo.dma.dp.ua/6035/1/SONAR.pdf,Figure2.
7https://repo.dma.dp.ua/6035/1/SONAR.pdf,Figure2.KDNY10-K2021.
8https://repo.dma.dp.ua/6035/1/SONAR.pdf,Figure2,Figure3.
9“SONAR:DoaNewStudyDesignandStatisticallySignificantResultsTranslatetoReliability?”,ClinicalJournaloftheAmericanSocietyofNephrology.
10/jasn/Fulltext/2014/05000/The_Endothelin_Antagonist_Atrasentan_Lowers.27.aspx,“ClinicalStudyProtocol”forSONAR.
11/jasn/Fulltext/2014/05000/The_Endothelin_Antagonist_Atrasentan_Lowers.27.aspx12“IndividualAtrasentanExposureisAssociatedWithLong-termKidneyandHeartFailureOutcomesinPatientsWithType2DiabetesandChronicKidneyDisease”,ClinicalPharmacologyandTherapeutics:“ERAsalsocausefluidretention,whichcanleadtoedemaandheartfailureinhigh-riskpatients.
13https://repo.dma.dp.ua/6035/1/SONAR.pdf
2/35
intheatrasentangroupthanintheplacebogroup.14,15,16SONARdatareflectsanincreaseinbrainnatriureticpeptideinpatientstreatedwithatrasentaninSONAR.BNPwasnormalforallpatientsenteringtreatment,butquicklybecameelevatedinatrasentanpatients.17Atrasentanisalsoassociatedwithastatistically-significantlyelevatedrateofanemia.18AnemiaisaseriousriskfactorfordiseaseprogressioninIgAN,animportantpatientpopulationforChinook.19,20,21Reportedmortalityonatrasentanwasnumericallyhigherthanreportedmortalityonplacebointhedouble-blindperiodoftheSONARtrial.22Thismortalityincreaseintheatrasentangroupisalsopresentintheenrichmentperiod.23Avosentan,adrugwithasimilarmechanismtoatrasentan,hadaclinicaltrialabruptlystoppedbecauseofanincreasedriskofheartfailure.24Studiesdoneonatrasentanandsimilardrugsshowthattheyraiseheartfailurerisk.25AsumofcardiaceventsfromtheFDAreportedadverseeffectsgives136heartfailureeventsonatrasentanand93onplacebo.26Averysmallstudyusinganarguablysuperiorbiomarker,inulin,tomeasureGFR,foundthatatrasentanseeminglymadeGFRworse.27Asdiscussedinfra,sparsentan,whichhasexclusiveorphandrugapprovalforreducingproteinuriainIgAN,islikelysafer,showingalessalarmingeffectonheartfailureandanemia.28
BothAbbVieandChinookappeartohavemanipulatedfactsandfigurestoconcealdangersassociatedwithatrasentan.AbbVieappearstohavemanipulatedgraphstomodifytheapparenteffectofatrasentanbyvisuallydistortingenrichmentandpost-treatmentperiods,therebymodifyingtheslopeofthedrugeffect.29AbbVieusedcompositeendpointsinitsdatathatconflatedpositiveandnegativeoutcomesfromatrasentan,whichrunscontrarytobestclinicalpractice.30TheSONARauthorsthenlabeltheseendpointsinamisleadingwayandincludequestionableendpointsincomposites,includingnon-fatalstrokefiguresthatentirelyreversethemeaningofcriticalendpoints.31Chinookappearstohavemisledinvestorsaboutthenumberofpatientsinwhichatrasentanwastrialed,likelytogiveafalseimpressionofdrugsafety.32Chinookhasalsomisrepresentedatrasentan’ssafetyprofilebyclaimingnoSAEsassociatedwith
14https://repo.dma.dp.ua/6035/1/SONAR.pdf.
15“SupplementaryAppendix”totheSONARtrial.
16/ct2/show/results/NCT01858532?term=atrasentan&draw=2&rank=5.17“SupplementaryAppendix”toSONAR,https://repo.dma.dp.ua/6035/1/SONAR.pdf.
18https://repo.dma.dp.ua/6035/1/SONAR.pdf
19/pmc/articles/PMC6340464/
20/pmc/articles/PMC3514188/
21/ajn/article-abstract/51/8/624/41630/The-Association-of-Low-Hemoglobin-Levels-with-IgA?redirectedFrom=fulltext
22https://repo.dma.dp.ua/6035/1/SONAR.pdf
23/ct2/show/results/NCT01858532?term=atrasentan&draw=2&rank=5
24https://repo.dma.dp.ua/6035/1/SONAR.pdf
25https://repo.dma.dp.ua/6035/1/SONAR.pdf
26SeeAppendix.
27/co-
nephrolhypertens/Fulltext/2021/07000/Endothelin_receptor_antagonists_for_the_treatment.13.aspx
28/journals/lancet/article/PIIS0140-6736(23)00569-X/fulltext
29https://repo.dma.dp.ua/6035/1/SONAR.pdf
30/pmc/articles/PMC2923692/
31https://repo.dma.dp.ua/6035/1/SONAR.pdf,
/ct2/show/results/NCT01858532?term=atrasentan&draw=2&rank=5
.
32SeeAppendix.
3/35
itorevidenceofsignificantfluidretention,neitherofwhichisaccurate.33ChinookhasmisleadinglypresenteddatabysuggestingthathemodynamicfactorsplayednoroleintheUACRresultsitshowed.34WhenChinookreportedonthisstudy,itmisleadinglygavepercentagesforpatientbenefitandadverseeffectratesdrawnfromdifferentsub-groupingsofthesample.35Theonlyplacebo-matcheddataonatrasentanfromChinookhasbeendelayedbyrequestoftheFDA,sothereisnoreasontoexpectthatthesafetyissuessuprahavebeen
36
overcome.
Introduction:OnStudyMethodology
Despitebeingdesignedtoreducetheoddsofseriousadverseeffects,theSONARtrialwasabruptlyhalted.37Weseeitastellingthatdespitethedesign,thedataindicatesincreasedriskofseriouscardiovasculareventsfromatrasentan.SONARmadeuseofanenrichment-basedstudydesign,inwhichpatientswerestratifiedinto“responder”and“non-responder”drugpopulationsfollowingasix-week“enrichment”periodonatrasentan.38Patientswereexcludedfromconsiderationiftheyhadaprevioushospitaladmissionforheartfailure,ahistoryofpulmonaryhypertension,anyknownnon-diabetickidneydisease,ahistoryofsevereperipheralorfacialoedema,orother-than-normallevelsofbrainnatriureticpeptide(amongothercriteria).39Patientswererequiredtoentertreatmentwithanangiotensinreceptorblockeroranangiotensin-convertingenzymeinhibitorandadiuretic,bothofwhichmeasureswereintendedtomakeheartfailurelesslikelyandrenalrepairmorelikely.40Then,alleligiblepatientsweregivenasix-weekroundofatrasentan,afterwhichtheywerestratifiedintoresponderandnon-responderpopulations.41Responderswerethosepatientswhoshoweda30%reductioninurinealbumin-to-creatinineratio,whodidnothavesubstantialfluidretention,anddidnotshowanincreaseinserumcreatinineduringtheenrichmentperiod—again,allmeasuresintendedtoensurethatthepopulationthatcontinuedinthetrialwouldbeaslikelyaspossibletobenefitfromthetreatment,andasunlikelyaspossibletosuffercardiovascularcomplications.42Only3,666patients—theresponderpopulationandabout1,000non-responders—enteredthedouble-blindtreatmentperiod,andonly2,648patientscompletedthestudy.43Aswenotesupra,thetrialwasthenabruptlyhalted.
Atrasentan:NoStructuralRepair
Weconcludethatthetrialdatashowedthatatrasentanisinefficaciousforchronickidneydisease.Thestudydatashowsthattherewasnostatisticallysignificantimprovementinadvancementto
33/file.cfm/52/docs/era_2022-atrasentan_affinity_igan-fc052.pdf,Slides8,12.34SeeAppendix.
35/file.cfm/52/docs/era_2022-atrasentan_affinity_igan-fc052.pdf,Slide8.36/chinook-delays-topline-kidney-condition-data-eluminex-ropes-in-40m-in-a-series-b/37/news/media-statements/abbvie-statement-on-sonar-study-closure.htm38https://repo.dma.dp.ua/6035/1/SONAR.pdf39https://repo.dma.dp.ua/6035/1/SONAR.pdf40https://repo.dma.dp.ua/6035/1/SONAR.pdf41https://repo.dma.dp.ua/6035/1/SONAR.pdf42https://repo.dma.dp.ua/6035/1/SONAR.pdf
43https://repo.dma.dp.ua/6035/1/SONAR.pdf;“Atrasentaninpatientswithdiabetesandchronickidneydisease”responseletter,LancetJanuary25,2020,VincenzoSepe,CarmeloLibetta.
4/35
end-stagerenaldiseaseintheatrasentanversustheplacebocohort,onlyanumericaldifferenceof14patientsandap-valueof0.06withapercentagedifferenceof5.1%to6.1%ofpatients.Aftercessationoftreatment,measurementsofthesurrogatebiomarkersconvergedbetweenthetreatmentandplaceboarms.Systolicbloodpressureconvergedbeforethetreatmentperiodwascomplete.Expertsinvolvedintheatrasentantrialswithwhomwespokeexplainedthattheeffectwas“functional”,not“structural”,maintainingthat,intheiropinions,therewassomepossibilityofastructuraleffectbecomingevidentinthefuture.
NoStatisticallySignificantImprovementinAdvancementtoEnd-StageRenalDisease
Atrasentan’sdirecteffectonratesofadvancementtoend-stagekidneydisease,asthebelowtabletakenfromtheSONARanalysisshows,doesnotreachstatisticalsignificance.Itisonlybyconflatingend-stagekidneydiseasewithotherrenalendpoints,atechniquewewilldiscussinfra,thatrenaloutcomescanbemadetoappearsignificant.44Differenceinend-stagekidneydisease,inthebelowtablefromtheSONARstudy,achievedap-valueof0.06.45Thenumericaldifferenceinadvancementtoend-stagerenaldiseasebetweenatrasentanandplacebogroupsamongresponderswasonly14patients,afigureovershadowedbytheexcesscardiovasculareventsexperiencedbypatientsinthetreatmentarmofSONAR.ThenumbersreportedtotheFDAreflectanevensmallerbetween-groupsdifferenceof8patients,withalowertotalnumberofeventsreported;it’snotobviouswhytheSONARauthorsgivedifferentESKDnumbersindifferentplaces.46
44https://repo.dma.dp.ua/6035/1/SONAR.pdf
45https://repo.dma.dp.ua/6035/1/SONAR.pdf
46/ct2/show/results/NCT01858532?term=atrasentan&draw=2&rank=5
5/35
AllDifferencesBetweenGroupsDisappearAfterTrial
FigurefromboththeRADARandSONARanalysesshowthatimportantsurrogatebiomarkersconvergebetweenatrasentanandplacebogroupsveryshortlyaftertreatmentcessation.47Thisisnottheresultweshouldexpectifatrasentanisslowingrenaldecline,becausebytheendofthetreatmentperiodthereshouldbesomelastingdifferenceinkidneyfunctionbetweenthegroups.Instead,theresultsweseearemuchmoreconsistentwithaconfoundingeffectofatrasentanonthesurrogatebiomarkersusedbythetrial,whichwouldnotreflectanyrealrenalbenefit.
Thebelowfigure,fromtheRADARtrial,48showsthatpatienturinealbumin-creatinineratios(UACR)convergedonly30daysaftertreatmentcessation(possiblysoonersincethiswastheonlyposttreatmentendpoint),withthelowerdosageatrasentangroup(whichusedthedoserecommendedtoavoidcardiovascularcomplications)actuallyshowinganincreaseinUACRoverplacebobytheendofthetrial:
ItisknownthatUACRisacorrelate,notadirectindicator,ofdiseaseseverity.49ButifUACR
returnstonormalimmediatelyafterdrugcessation,weseethatishasnotbeenareliablecorrelate,becauseitsinitialreductionevidentlyhasnotreflectedarealchangeinkidneyfunctionbutlikelyadirecthemodynamicchangeonthecorrelateitself.
47/jasn/Fulltext/2014/05000/The_Endothelin_Antagonist_Atrasentan_Lowers.27.aspx,
https://repo.dma.dp.ua/6035/1/SONAR.pdf
.
48/jasn/Fulltext/2014/05000/The_Endothelin_Antagonist_Atrasentan_Lowers.27.aspx.Thestudypoolstwotrials,oneofwhichwastheRADARtrial.
49/cjasn/pages/articleviewer.aspx?year=2020&issue=06000&article=00023&type=Fulltext.Emphasisadded:“SONARwasdesignedonthebasisoftheobservationthatriskofprogressivekidneydiseaseiscorrelatedtoalbuminuria…Therearecaveatstotheusefulnessofthisdesign.Mostimportantly,thebiologicresponseismostlikelytopredictaclinicaltreatmentresponseifthebiologicresponseliesonthecausalpathway.
Historytellsusthatourassumptionsthatassociationsbetweenbiologicresponsesandclinicalresponse,nomatterhowconsistentandstrong,arecausal,arefrequentlyincorrect.”
6/35
Theabovetableshowsaremarkablyrapideffectonalbuminuriaatthebeginningandendofthetreatmentperiod.Ifalbuminuriais,inthiscase,tobetakenasanindicatorofrenalhealth,weshouldexpectthealbuminuriato(1)declineslowlyafterdruginitiation,asthekidneyimproves,and(2)remainlowerthanatbaselineafterdrugcessation.Aswesee,neitherofthesearethecase:albuminuriadeclinessharplyassoonastreatmentisinitiated,andthen,moreimportantly,differencesbetweengroupsdisappearafterdrugcessation.Asthestudyfound(emphasisadded):50
Attheendofthe30-dayfollow-upperiodwithoutstudymedication,themedianUACRswere737±912mg/g,1051±1206mg/g,and727±821mg/gfortheplacebo,0.75mg/d,and1.25mg/dgroups,respectively.Thegeometricmeanchangesfrombaselinetorecoverywere−5.3%,+4.3%,and−7.8%fortheplacebo,0.75mg/d,and1.25mg/dgroups,respectively,thusshowingthatUACRvalu
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 人工智能领域人工智能技术应用与创新解决方案
- Unit5WhatanAdventure!Understandingideas教学设计高一英语
- 七年级语文上册 第六单元 22《我的长生果》教学设计2 冀教版
- 乘用车行业新能源汽车推广方案
- 八年级物理下册 6.1怎样认识力教案 (新版)粤教沪版
- 五年级数学下册教案8.1复式条形统计图-北师大版
- 2016年0423四川公务员考试《行测》真题参考答案及解析
- 高考物理 母题小题精做系列 07(第01期)(含解析)
- 2024年三年级品社下册《合作的乐趣》教案 北师大版
- 2024年隔离接地开关项目发展计划
- 皮肤科护理中的急救与危重病人抢救
- 燃煤锅炉培训课件
- 浅谈小学语文课外阅读教学中传统文化教育的渗透获奖科研报告
- 行TACE手术的护理查房课件
- 《三国演义》中诸葛亮人物形象分析
- 第三脑室肿瘤查房课件
- 2023年常减压蒸馏操作工考试真题模拟汇编(共218题)
- 2023年10月民航中南空管局招考聘用应届毕业生笔试历年难易错点考题荟萃附带答案详解
- 教科版小学二年级科学下册-《皮肤很重要》原创课件
- 酒水库房管理制度
- R语言数据挖掘课件
评论
0/150
提交评论